CNTX Stock Price, Context Therapeutics . Quote, Chart

Market Summary

USD1.38+0.08

Market Closed

6.15%

CNTX Stock Price

View Fullscreen

CNTX RSI Chart

CNTX Valuation

Market Cap

22.0M

Price/Earnings (Trailing)

-0.92

Price/Free Cashflow

-1.05

CNTX Price/Earnings (Trailing)

CNTX Profitability

Return on Equity

-201.87%

Return on Assets

-149.19%

Free Cashflow Yield

-95.53%

CNTX Fundamentals

CNTX Earnings

Earnings (TTM)

-24.0M

Earnings Growth (Yr)

-90.34%

Earnings Growth (Qtr)

-15.24%

Breaking Down CNTX Revenue

Last 7 days

-2.1%

Last 30 days

8.7%

Last 90 days

42.3%

Trailing 12 Months

140.5%

How does CNTX drawdown profile look like?

CNTX Financial Health

Current Ratio

3.83

CNTX Investor Care

Diluted EPS (TTM)

-1.5

Tracking the Latest Insider Buys and Sells of Context Therapeutics Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 21, 2023	lehr martin a.	bought	4,900	0.8415	5,823	chief executive officer
Feb 13, 2023	lehr martin a.	bought	4,900	0.8742	5,606	chief executive officer
Feb 06, 2023	lehr martin a.	bought	4,900	0.9723	5,040	chief executive officer
Jan 30, 2023	lehr martin a.	bought	4,900	0.6974	7,027	chief executive officer
Jan 23, 2023	lehr martin a.	bought	4,900	0.7166	6,839	chief executive officer
Jan 17, 2023	lehr martin a.	bought	4,995	0.7364	6,783	chief executive officer
Dec 16, 2022	lehr martin a.	bought	14,796	0.7398	20,000	chief executive officer
Dec 16, 2022	minai-azary jennifer lynn	bought	18,500	0.74	25,000	chief financial officer
Dec 09, 2022	levit alex c.	bought	5,094	0.8491	6,000	chief legal officer, corp. sec
Aug 19, 2022	lehr martin a.	bought	24,064	1.8511	13,000	chief executive officer

Which funds bought or sold CNTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Mar 11, 2024	VANGUARD GROUP INC	added	0.42	-222,677	673,494	-%
Feb 14, 2024	STATE STREET CORP	unchanged	-	-12,505	37,185	-%
Feb 14, 2024	BANK OF AMERICA CORP /DE/	added	9.00	-28.00	123	-%
Feb 14, 2024	Mill Creek Capital Advisors, LLC	unchanged	-	-39,760	118,233	-%
Feb 14, 2024	Ally Bridge Group (NY) LLC	unchanged	-	-275,861	820,325	0.49%
Feb 14, 2024	Retirement Group, LLC	unchanged	-	-59.00	175	-%
Feb 14, 2024	Opaleye Management Inc.	new	-	1,101,750	1,101,750	0.29%
Feb 14, 2024	UBS OCONNOR LLC	added	0.33	-111,264	335,243	0.02%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	unchanged	-	-40,208	119,564	-%

Are Funds Buying or Selling CNTX?

Are funds buying CNTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CNTX

No. of Funds

Unveiling Context Therapeutics Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	affinity asset advisors, llc	2.06%	328,817	SC 13G/A
Feb 07, 2024	lehr martin a.	8.8%	1,452,466	SC 13G/A
Jan 05, 2024	opaleye management inc.	5.14%	820,000	SC 13G
Feb 14, 2023	context therapeutics inc.	7.3%	1,186,102	SC 13G
Jan 10, 2023	sabby management, llc	4.99%	796,706	SC 13G/A
Jan 09, 2023	hirschman orin	0%	0	SC 13G/A
Oct 27, 2022	hirschman orin	8.1%	1,285,771	SC 13G
May 09, 2022	affinity asset advisors, llc	5.53%	883,654	SC 13G
Feb 02, 2022	hudson bay capital management lp	8.36%	1e+06	SC 13G

Recent SEC filings of Context Therapeutics Inc.

View All Filings

Date Filed	Form Type	Document
Apr 01, 2024	8-K	Current Report
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	4	Insider Trading
Mar 21, 2024	S-8	Employee Benefits Plan
Mar 21, 2024	8-K	Current Report
Mar 21, 2024	10-K	Annual Report
Mar 06, 2024	8-K	Current Report
Feb 13, 2024	SC 13G/A	Major Ownership Report
Feb 07, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to Context Therapeutics Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	40.6B	6.8B	-1.15%	-18.78%	-8.61	5.92	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.46%	-27.26%	-41.1	9.9	76.23%	61.08%
BMRN	15.5B	2.4B	-6.36%	-11.66%	92.47	6.41	15.42%	18.43%
INCY	11.5B	3.7B	-9.50%	-30.40%	19.23	3.11	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-18.85%	-43.46%	-10.92	14.56	425.83%	18.94%
BBIO	4.3B	-	-18.25%	70.26%	-6.55	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-6.76%	2.03%	-14.16	12.52	440.80%	-27.84%
ARWR	2.7B	240.7M	-21.52%	-38.49%	-9.13	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-8.32%	-19.69%	-43.85	3.7	40.45%	71.62%
SMALL-CAP
CPRX	1.7B	398.2M	-6.79%	-8.36%	24.23	4.35	85.90%	-14.05%
NVAX	552.8M	983.7M	-16.14%	-47.54%	-1.01	0.56	-50.36%	17.16%
CRBP	351.2M	881.7K	-7.41%	335.24%	-7.87	466.16	-77.61%	-5.33%
INO	236.5M	4.9M	-18.26%	4.12%	-1.75	48.6	-54.97%	51.71%
IBIO	5.9M	2.1M	47.83%	55.96%	-0.22	2.14	-13.45%	66.37%

Context Therapeutics Inc. News

Latest updates

Context Therapeutics Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet														(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2019Q4
Assets	-30.1%	16.00	23.00	28.00	32.00	38.00	42.00	45.00	47.00	51.00	2.00	2.00	1.00	1.00	0.00
Current Assets	-30.1%	16.00	23.00	28.00	32.00	38.00	42.00	44.00	47.00	51.00	0.00	-	-	0.00	0.00
Cash Equivalents	-33.6%	14.00	22.00	25.00	30.00	35.00	39.00	43.00	46.00	50.00	0.00	1.00	2.00	0.00	0.00
Net PPE	-14.2%	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	-	-	-	-	-	-
Liabilities	-9.0%	4.00	5.00	4.00	3.00	3.00	4.00	3.00	2.00	3.00	4.00	6.00	8.00	10.00	24.00
Current Liabilities	-9.0%	4.00	5.00	4.00	3.00	3.00	4.00	3.00	2.00	3.00	4.00	-	-	10.00	24.00
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	-	-	-	6.00	21.00
Shareholder's Equity	-35.4%	12.00	18.00	24.00	29.00	35.00	38.00	42.00	45.00	48.00	-	-	-	-	-
Retained Earnings	-11.0%	-68.05	-61.28	-55.40	-50.40	-44.09	-40.53	-36.70	-32.69	-29.25	-26.20	-	-	-18.80	-25.44
Additional Paid-In Capital	0.3%	80.00	80.00	79.00	79.00	79.00	79.00	78.00	78.00	78.00	3.00	-	-	2.00	1.00
Shares Outstanding	0%	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	16.00	-	0.00	0.00	0.00	0.00
Float	-	-	-	24.00	-	-	-	32.00	-	-	-	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)															(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Cashflow From Operations	-108.8%	-7,227	-3,460	-4,631	-5,728	-3,929	-2,994	-2,805	-3,820	-4,961	-43.63	-2,078	-1,715	-	-	-
Share Based Compensation	0.4%	256	255	283	283	244	277	241	215	204	162	119	26.00	-	-	-
Cashflow From Investing	-	-	-	-	-	-	-500	-1.84	-35.00	-	-	-250	-	-	-	-
Cashflow From Financing	-	-	-	-	-	-	-	-	-102	54,228	-816	1,948	3,035	-	-	-

CNTX Income Statement

2023-12-31

Consolidated Statements of Operations - USD ($)	12 Months Ended
Consolidated Statements of Operations - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Acquired in-process research and development	$ 0	$ 500,000
Research and development	17,782,731	7,091,163
General and administrative	7,289,885	7,790,040
Loss from operations	(25,072,616)	(15,381,203)
Interest income	1,163,975	547,268
Other expense	(55,570)	(2,004)
Net loss	$ (23,964,211)	$ (14,835,939)
Net income (loss) per share - basic (in dollars per share)	$ (1.50)	$ (0.93)
Net income (loss) per share - diluted (in dollars per share)	$ (1.50)	$ (0.93)
Weighted average common shares outstanding - basic (in shares)	15,966,053	15,966,053
Weighted average common shares outstanding - diluted (in shares)	15,966,053	15,966,053

CNTX Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($)	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 14,449,827	$ 35,497,445
Prepaid expenses and other current assets	1,597,384	2,356,213
Total current assets	16,047,211	37,853,658
Operating lease right-of-use asset	0	51,967
Property and equipment, net	15,524	27,568
Other assets	0	32,750
Total assets	16,062,735	37,965,943
Current liabilities:
Accounts payable	2,383,016	936,330
Accrued expenses and other current liabilities	1,808,699	2,216,169
Operating lease liability - current	0	55,078
Total current liabilities	4,191,715	3,207,577
Total liabilities	4,191,715	3,207,577
Commitments and contingencies
Stockholders' equity:
Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 15,966,053 issued and outstanding at December 31, 2023 and December 31, 2022	15,966	15,966
Additional paid-in capital	79,909,644	78,832,779
Accumulated deficit	(68,054,590)	(44,090,379)
Total stockholders' equity	11,871,020	34,758,366
Total liabilities and stockholders' equity	$ 16,062,735	$ 37,965,943

About Context Therapeutics Inc.

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CEO	Mr. Martin A. Lehr
WEBSITE	contexttherapeutics.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Context Therapeutics Inc. Frequently Asked Questions

What is the ticker symbol for Context Therapeutics Inc.? What does CNTX stand for in stocks?

CNTX is the stock ticker symbol of Context Therapeutics Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Context Therapeutics Inc. (CNTX)?

As of Thu Apr 25 2024, market cap of Context Therapeutics Inc. is 22.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CNTX stock?

You can check CNTX's fair value in chart for subscribers.

What is the fair value of CNTX stock?

You can check CNTX's fair value in chart for subscribers. The fair value of Context Therapeutics Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Context Therapeutics Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CNTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Context Therapeutics Inc. a good stock to buy?

The fair value guage provides a quick view whether CNTX is over valued or under valued. Whether Context Therapeutics Inc. is cheap or expensive depends on the assumptions which impact Context Therapeutics Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CNTX.